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Abstract
Two patients with Sjogren-Larsson syndrome were treated with calcipotriol in 
ointment and the ointment base only Tor 12 weeks, using a double-blind bilater­
ally paired comparative study. Unilateral improvement was observed in both 
patients in favour of the calcipotriol-treated side, The present case is the first 
demonstration of a substantial clinical effect of calcipotriol in the Sjogren-Lars­
son syndrome.
Introduction Biochemically, a deficiency of the fatty aldehyde dehy­
drogenase component [7| of the fatty alcohol:NAD+ oxi-
The Sjogren-Larsson syndrome (SLS) is a rare, autoso- doreductase complex has been established in cultured fibro-
mal recessively inherited dirsorder with an estimated inci- blasts and leucocytes [8, 9], while a partial reduction has
dence of 1:200,000. Characterizing features of this neuro- been reported in obligate carriers [1()|. Using a histochemi-
ectodermal genodermatosis are ichthyosis and neurologic cal technique, a deficiency of fatty alcohol:NAD+ oxidorc-
manifestations, while a number of associated symptoms ductase activity in the epidermis and jejunal mucosa has
may be present. The outstanding clinical feature of ichthyo- been demonstrated [11].
sis in SLS is the congenital, yellowish to dark brown, kera- This enzyme deficiency may constitute the biochemical
totic lichénification of the skin. Signs of the neurologic link between the skin and neurologic symptoms, for fatty
manifestations, i.e. pathologic reflexes, muscular hyperto- alcohol:NAD+ oxidureductase deficiency causes accumu-
nia, spastic di-or tetraplegia and mental retardation, usually lation of fatty alcohols in keratinocytes and neurons. The
emerge between 4 and 30 months of age and are stationary fatty alcohols are subsequently incorporated into lipids cs-
after puberty [!]. High-field magnetic resonance imaging sential for normal cell membrane functions. Recently, hovv-
may reveal atrophic changes of the cerebral motor area, ever, 2 patients with the typical clinical features of SLS
extrapyramidal system, corpus callosum and spinal cord have been reported with normal fatty alcohol:NAD+ oxi-
[2]. SLS may be associated with a variety of other anoma- doreductase activity, possibly suggesting that SLS is a hete-
lies. The presence of glistening dots on the macular region rogeneous disease [12, 13).
o f the retina is regarded as pathognomonic, although not Vitamin D, (dihydroxycholecalciferoi) causes a dose-
present in all patients. These dots are due to focal microglia dependent decrease in proliferation and an increase in dif-
degeneration and lead to impaired central vision (3, 4J. ferentiation of human cultured keratinocytes [14]. Clinical
Amblyopia may further reduce visual acuity [5]. Hyperke- data indicate that externally applied vitamin is effective
ratosis of plams and soles as well as joint hyperextensibil- in alleviating psoriasis, where proliferative activity of the
ity have been reported in association with the SLS [6J. epidermis is greatly increased [15], This study was part of a
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Discussion Apart from symptomatic therapies improving skin man
ifestations, a substitutional treatment has been proposed, i 
This is the first demonstration of a therapeutic effect of order to correct the basic lipid disorder underlying both dei 
topical calcipotriol in the SLS. In the present study, no clin- matologic and neurologic symptoms [21, 22].
ical side-effects or laboratory abnormalities were found. An interesting speculation is the possible amelioratio
Previous reports on topical treatment with Ia,25-dihy- of the neurologic symptoms by supplementation of dopu
droxyvitamin D^  as well as systemic treatment with la - mine agonists, since severely reduced dopamine concentri)
hydroxy vitamin D, of autosomal dominant ichthyosis vul- tions have been found in the putamen and, to a lesse
garis (ADIV) and X-linked recessive ichthyosis (XRI) extent, in the substantia nigra and other striatal regioni
showed an ineffectiveness of vitamin D< [17, 18]. suggesting a specific mono-aminergic dysfunction in pa
Frost [19] established hyperproliferation to be a contrib- tients with SLS [23],
uting factor in the pathogenesis of lamellar ichthyosis and Further research remains to be done, in order to offe
epidennolytic hyperkeratosis, but not in ADIV and XRI, the patient with SLS a substitutional treatment, amelioratin;
using autoradiographic techniques with tritiated thymidine both skin and neurologic symptoms. At the moment though
which is incorporated into cells in the period of DNA syn- symptomatic treatment of the skin manifestations remain
thesis. Jagell and Liden ¡20] demonstrated the DNA syn- important. Topical calcipotriol constitutes a new and prom
thesis of epidermal cells in SLS to be 2.7 times greater than ising approach in alleviating the ichthyosis in SLS, 
normal, using the same technique. Therefore, the ichthyo-
sis in SLS is characterized by hyperproliferation, whereas 
ADIV and XRI represent normoproliferative ichthyoses, 
possibly explaining the differences in clinical efficacy of 
the treatment with vitamin D* analogues.
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